{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T16:15:28Z","timestamp":1776701728710,"version":"3.51.2"},"reference-count":58,"publisher":"Oxford University Press (OUP)","issue":"23","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,12,1]]},"DOI":"10.2146\/ajhp090672","type":"journal-article","created":{"date-parts":[[2010,11,23]],"date-time":"2010-11-23T00:04:33Z","timestamp":1290470673000},"page":"2015-2024","source":"Crossref","is-referenced-by-count":29,"title":["Doripenem: A new carbapenem antibiotic"],"prefix":"10.1093","volume":"67","author":[{"given":"Elias B.","family":"Chahine","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary J.","family":"Ferrill","sequence":"additional","affiliation":[{"name":"Lloyd L. Gregory School of Pharmacy, Palm Beach Atlantic University, West Palm Beach, FL 33416"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mara N.","family":"Poulakos","sequence":"additional","affiliation":[{"name":"Lloyd L. Gregory School of Pharmacy, Palm Beach Atlantic University, West Palm Beach, FL 33416"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"key":"key\n\t\t\t\t2019041104325604300_b1-0672015","unstructured":"Infectious Diseases Society of America. Bad bugs, no drugs: as antibiotics discovery stagnates . . . a public health crisis brews. www.idsociety.org (accessed 2009 Dec 11)."},{"issue":"suppl 4","key":"key\n\t\t\t\t2019041104325604300_b2-0672015","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1186\/cc6820","article-title":"Gram-negative antibiotic resistance: there is a price to pay","volume":"12","author":"Slama","year":"2008","journal-title":"Crit Care"},{"issue":"suppl 1","key":"key\n\t\t\t\t2019041104325604300_b3-0672015","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1086\/599810","article-title":"Antimicrobial resistance among and therapeutic options against gram-negative pathogens","volume":"49","author":"Rahal","year":"2009","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019041104325604300_b4-0672015","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1592\/phco.27.2.227","article-title":"Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections","volume":"27","author":"Drew","year":"2007","journal-title":"Pharmacotherapy"},{"key":"key\n\t\t\t\t2019041104325604300_b5-0672015","volume-title":"Doribax (doripenem) product monograph","year":"2007"},{"key":"key\n\t\t\t\t2019041104325604300_b6-0672015","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S0025-7125(16)30037-2","article-title":"Carbapenems","volume":"79","author":"Norrby","year":"1995","journal-title":"Med Clin North Am"},{"issue":"suppl A","key":"key\n\t\t\t\t2019041104325604300_b7-0672015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/24.suppl_A.1","article-title":"The carbapenems: new broad spectrum beta-lactam antibiotics","volume":"24","author":"Moellering","year":"1989","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t2019041104325604300_b8-0672015","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1128\/AAC.48.4.1313-1319.2004","article-title":"Comparative activities of doripenem versus isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp. with characterized beta-lactamases","volume":"48","author":"Mushtaq","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019041104325604300_b9-0672015","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.diagmicrobio.2004.12.008","article-title":"Comparative activity of doripenem and three other carbapenems tested against gram-negative bacilli with various beta-lactamase resistance mechanisms","volume":"52","author":"Jones","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"key":"key\n\t\t\t\t2019041104325604300_b10-0672015","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1093\/jac\/37.5.1034","article-title":"Comparative stability of carbapenem and penem antibiotics to human recombinant dehydropeptidase-1","volume":"37","author":"Mori","year":"1996","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t2019041104325604300_b11-0672015","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1128\/AAC.42.1.94","article-title":"In vitro and in vivo antibacterial activities of S-4661, a new carbapenem","volume":"42","author":"Tsuji","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019041104325604300_b12-0672015","doi-asserted-by":"crossref","first-page":"199","DOI":"10.7164\/antibiotics.49.199","article-title":"A novel 1 beta- methylcarbapenem antibiotic, S-4661. Synthesis and structure-activity relationships of 2-(5-substituted pyrrolidin-3-ylthio)-1 beta-methylcarbapenems","volume":"49","author":"Iso","year":"1996","journal-title":"J Antibiot (Tokyo)"},{"key":"key\n\t\t\t\t2019041104325604300_b13-0672015","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1128\/AAC.48.8.3136-3140.2004","article-title":"Activities of doripenem (S-4461) against drug-resistant clinical pathogens","volume":"48","author":"Jones","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019041104325604300_b14-0672015","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1093\/jac\/dkh298","article-title":"Doripenem (S-4661), a novel car-bapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations","volume":"54","author":"Jones","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t2019041104325604300_b15-0672015","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2165\/00003088-200039030-00002","article-title":"Comparative pharmacokinetics of the carbapenems: clinical implications","volume":"39","author":"Mouton","year":"2000","journal-title":"Clin Pharmacokinet"},{"key":"key\n\t\t\t\t2019041104325604300_b16-0672015","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.2165\/00003495-200767070-00006","article-title":"Comparative review of the carbapenems","volume":"67","author":"Zhanel","year":"2007","journal-title":"Drugs"},{"key":"key\n\t\t\t\t2019041104325604300_b17-0672015","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1517\/13543784.11.4.529","article-title":"Recent developments in carbapenems","volume":"11","author":"Bonfiglio","year":"2002","journal-title":"Expert Opin Investig Drugs"},{"key":"key\n\t\t\t\t2019041104325604300_b18-0672015","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/jac\/36.1.53","article-title":"Potent activity of meropenem against Escherichia coli arising from its simultaneous binding to penicillin-binding proteins 2 and 3","volume":"36","author":"Sumita","year":"1995","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t2019041104325604300_b19-0672015","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1128\/AAC.16.3.325","article-title":"Competition of beta-lactam antibiotics for the penicillin-binding proteins of Pseudomonas aeruginosa, Enterobacter cloacae, Klebsiella aerogenes, Proteus rettgeri, and Escherichia coli: comparison with antibacterial activity and effects upon bacterial morphology","volume":"16","author":"Curtis","year":"1979","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019041104325604300_b20-0672015","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/jac\/12.2.119","article-title":"Mode of action of ceftazidime: affinity for the penicillin-binding proteins of Escherichia coli K12, Pseudomonas aeruginosa and Staphylococcus aureus","volume":"12","author":"Hayes","year":"1983","journal-title":"Antimicrob Chemother"},{"key":"key\n\t\t\t\t2019041104325604300_b21-0672015","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ijantimicag.2008.08.015","article-title":"In vitro activity of doripenem against Acinetobacter baumannii clinical isolates","volume":"33","author":"Marti","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"key\n\t\t\t\t2019041104325604300_b22-0672015","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1111\/j.1469-0691.2005.01271.x","article-title":"Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003)","volume":"11","author":"Fritsche","year":"2005","journal-title":"Clin Microbiol Infect"},{"key":"key\n\t\t\t\t2019041104325604300_b23-0672015","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.diagmicrobio.2009.01.019","article-title":"Antimicrobial activity of doripenem tested against prevalent gram-positive pathogens: results from a global surveillance study (2003\u20132007)","volume":"63","author":"Fritsche","year":"2009","journal-title":"Diagn Microbiol Infect Dis"},{"key":"key\n\t\t\t\t2019041104325604300_b24-0672015","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1128\/AAC.48.8.3136-3140.2004","article-title":"Activities of doripenem (S-4661) against drug-resistant clinical pathogens","volume":"48","author":"Jones","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019041104325604300_b25-0672015","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.diagmicrobio.2009.02.002","article-title":"Doripenem activity tested against a global collection of Enterobacteriaceae, including isolates resistant to other extended-spectrum agents","volume":"63","author":"Mendes","year":"2009","journal-title":"Diagn Microbiol Infect Dis"},{"key":"key\n\t\t\t\t2019041104325604300_b26-0672015","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.diagmicrobio.2009.01.025","article-title":"In vitro potency of doripenem tested against an international collection of rarely isolated bacterial pathogens","volume":"63","author":"Jones","year":"2009","journal-title":"Diagn Microbiol Infect Dis"},{"key":"key\n\t\t\t\t2019041104325604300_b27-0672015","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.diagmicrobio.2004.12.008","article-title":"Comparative activity of doripenem and three other carbapenems tested against gram-negative bacilli with various beta-lactamase resistance mechanisms","volume":"52","author":"Jones","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"key":"key\n\t\t\t\t2019041104325604300_b28-0672015","doi-asserted-by":"crossref","first-page":"4413","DOI":"10.1128\/AAC.49.10.4413-4417.2005","article-title":"In vitro activities of doripenem and comparator agents against 364 anaerobic clinical isolates","volume":"49","author":"Wexler","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019041104325604300_b29-0672015","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.diagmicrobio.2009.01.022","article-title":"Activity of a novel carbapenem, doripenem, against anaerobic pathogens","volume":"63","author":"Goldstein","year":"2009","journal-title":"Diagn Microbiol Infect Dis"},{"key":"key\n\t\t\t\t2019041104325604300_b30-0672015","doi-asserted-by":"crossref","first-page":"3944","DOI":"10.1128\/AAC.49.9.3944-3947.2005","article-title":"Use of pharmacokinetic- pharmacodynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem","volume":"49","author":"Bhavnani","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019041104325604300_b31-0672015","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.diagmicrobio.2008.06.016","article-title":"Pharmacodynamic assessment of doripenem in peritoneal fluid against gram-negative organisms: use of population pharmacokinetic modeling and Monte Carlo simulation","volume":"62","author":"Ikawa","year":"2008","journal-title":"Diagn Microbiol Infect Dis"},{"key":"key\n\t\t\t\t2019041104325604300_b32-0672015","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1128\/AAC.01252-07","article-title":"In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures","volume":"52","author":"Kim","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019041104325604300_b33-0672015","doi-asserted-by":"crossref","first-page":"4352","DOI":"10.1128\/AAC.00282-09","article-title":"In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa","volume":"53","author":"Crandon","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019041104325604300_b34-0672015","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1128\/AAC.00424-08","article-title":"Disposition, metabolism, and excretion of [14C]doripenem after a single 500- milligram intravenous infusion in healthy men","volume":"52","author":"Cirillo","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019041104325604300_b35-0672015","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.ijantimicag.2008.08.031","article-title":"Pharmacokinetic-pharmacodynamic target attainment analysis of doripenem in infected patients","volume":"33","author":"Ikawa","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"key\n\t\t\t\t2019041104325604300_b36-0672015","first-page":"91","article-title":"Pharmacokinetics and tissue penetration of a new carbapenem, doripenem, intravenously administered to laboratory animals","volume":"20","author":"Hori","year":"2006","journal-title":"In Vivo"},{"key":"key\n\t\t\t\t2019041104325604300_b37-0672015","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1093\/jac\/dkm371","article-title":"Peritoneal penetration of doripenem after intravenous administration in abdominal-surgery patients","volume":"60","author":"Ikawa","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t2019041104325604300_b38-0672015","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1177\/0091270009337012","article-title":"Pharmacokinetics, safety, and tolerability of doripenem after 0.5-, 1-, and 4-hour infusions in healthy volunteers","volume":"49","author":"Cirillo","year":"2009","journal-title":"J Clin Pharmacol"},{"key":"key\n\t\t\t\t2019041104325604300_b39-0672015","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.diagmicrobio.2009.01.027","article-title":"Pharmacokinetic-pharmacodynamic modeling to support doripenem dose regimen optimization for critically ill patients","volume":"63","author":"Van Wart","year":"2009","journal-title":"Diagn Microbiol Infect Dis"},{"key":"key\n\t\t\t\t2019041104325604300_b40-0672015","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.1128\/AAC.00426-09","article-title":"Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007","volume":"53","author":"Hawser","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"6, suppl 1","key":"key\n\t\t\t\t2019041104325604300_b41-0672015","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/j.amjmed.2006.03.012","article-title":"Antimicrobial resistance in gram-positive bacteria","volume":"119","author":"Rice","year":"2006","journal-title":"Am J Med"},{"key":"key\n\t\t\t\t2019041104325604300_b42-0672015","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1056\/NEJMra041359","article-title":"The new beta-lactamases","volume":"352","author":"Jacoby","year":"2005","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041104325604300_b43-0672015","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1097\/CCM.0b013e3181691b99","article-title":"Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study","volume":"36","author":"Chastre","year":"2008","journal-title":"Crit Care Med"},{"key":"key\n\t\t\t\t2019041104325604300_b44-0672015","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.clinthera.2008.04.019","article-title":"Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study","volume":"30","author":"Lucasti","year":"2008","journal-title":"Clin Ther"},{"key":"key\n\t\t\t\t2019041104325604300_b45-0672015","doi-asserted-by":"crossref","first-page":"3782","DOI":"10.1128\/AAC.00837-08","article-title":"Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis","volume":"53","author":"Naber","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019041104325604300_b46-0672015","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1185\/03007990802179255","article-title":"Efficacy and safety of doripenem versus piperacillin\/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study","volume":"24","author":"R\u00e9a-Neto","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"key\n\t\t\t\t2019041104325604300_b47-0672015","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1128\/AAC.01133-08","article-title":"Urinary bactericidal activity of doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis","volume":"53","author":"Wagenlehner","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"suppl 1","key":"key\n\t\t\t\t2019041104325604300_b48-0672015","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1086\/599811","article-title":"In vitro activity of doripenem","volume":"49","author":"Sahm","year":"2009","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019041104325604300_b49-0672015","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1093\/jac\/dkp134","article-title":"Successful treatment with doripenem and tobramycin of ventriculitis due to imipenem- and meropenem-resistant Pseudomonas aeruginosa","volume":"63","author":"Gelfand","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t2019041104325604300_b50-0672015","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.tox.2006.02.004","article-title":"Absence of convulsive liability of doripenem, a new carbapenem antibiotic, in comparison with beta-lactam antibiotics","volume":"222","author":"Horiuchi","year":"2006","journal-title":"Toxicology"},{"issue":"suppl 1","key":"key\n\t\t\t\t2019041104325604300_b51-0672015","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1086\/599813","article-title":"Safety of intravenous infusion of doripenem","volume":"49","author":"Redman","year":"2009","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019041104325604300_b52-0672015","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1111\/j.1468-3083.2008.03079.x","article-title":"Doripenem-induced intertriginous drug eruption as a mild form of AGEP","volume":"23","author":"Sawada","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"key\n\t\t\t\t2019041104325604300_b53-0672015","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1080\/03602530701690341","article-title":"Interaction between valproic acid and carbapenem antibiotics","volume":"39","author":"Mori","year":"2007","journal-title":"Drug Metab Rev"},{"key":"key\n\t\t\t\t2019041104325604300_b54-0672015","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1124\/dmd.104.000661","article-title":"Mechanism of the drug interaction between valproic acid and carbapenem antibiotics in monkeys and rats","volume":"32","author":"Nakajima","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"key\n\t\t\t\t2019041104325604300_b55-0672015","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/j.clinthera.2008.11.013","article-title":"Stability of doripenem in vitro in representative infusion solutions and infusion bags","volume":"30","author":"Psathas","year":"2008","journal-title":"Clin Ther"},{"key":"key\n\t\t\t\t2019041104325604300_b56-0672015","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.2146\/ajhp070574","article-title":"Compatibility of doripenem with other drugs during simulated Y-site administration","volume":"65","author":"Brammer","year":"2008","journal-title":"Am J Health-Syst Pharm"},{"issue":"1278","key":"key\n\t\t\t\t2019041104325604300_b57-0672015","first-page":"5","article-title":"Doripenem (Doribax)\u2014a new parenteral carbapenem","volume":"50","year":"2008","journal-title":"Med Lett Drugs Ther"},{"key":"key\n\t\t\t\t2019041104325604300_b58-0672015","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.clinthera.2008.04.001","article-title":"Hospital resource utilization with doripenem versus imipenem in the treatment of ventilator-associated pneumonia","volume":"30","author":"Merchant","year":"2008","journal-title":"Clin Ther"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/67\/23\/2015\/28345277\/ajhp2015.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,14]],"date-time":"2020-06-14T01:06:48Z","timestamp":1592096808000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/67\/23\/2015\/5129935"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12,1]]},"references-count":58,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2010,12,1]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp090672","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2010,12,1]]},"published":{"date-parts":[[2010,12,1]]}}}